EMA urges cooperation to ensure ethics, GCP of trials

By Nick Taylor

- Last updated on GMT

Related tags Clinical trials Clinical trial Good clinical practice Pharmaceutical industry

The EMA has published its thoughts on monitoring overseas trials and will seek to establish an international network of regulators to develop and implement a robust oversight framework.

European drug marketing applications are increasingly supported by clinical trials conducted outside the region. In response to this a series of measures have been taken over the past six years, leading to the formation of a working group tasked with developing practical proposals.

The group has now published a reflection paper​ looking at the ethical and good clinical practice (GCP) aspects of clinical trials conducted outside the European Economic Area (EEA). Central to the ideas expressed in the document is the need for regulators to communicate and cooperate.

By forging stronger links with overseas regulators the working group hopes the European Medicine Agency (EMA) will be able to establish six elements that must be in place for all trials.

These goals call for: truly independent ethics committees; systems of follow-up of clinical trials; use of GCP to control studies before during and after conduct; and refusal of marketing approval if trials are noncompliant.

Selecting initiatives

Ensuring these aspects are in place for all trials “is a long-term goal​” which will be worked towards in a phased manner. Limited resources mean that prioritisation is required. Countries which conduct a lot of trials and those with limited regulatory systems will be prioritised.

Actions should also be complementary to initiatives implemented by other international, European, regional and national bodies in the field. This is intended to avoid duplication of efforts, ensure all necessary measures are taken and help regulators learn from previous initiatives.

After considering the priorities and other organisations’ actions the EMA should implement measures which: increase the efficiency and effectiveness of GCP inspection; improve capacity of national regulators; and motivate sponsors to ensure adequate levels of clinical trial controls.

Other topics

The document also covers a number of practical and regulatory topics related to overseas clinical trials. Specifically relating to ethical standards of clinical trials the document discusses consent procedures, confidentiality, fair compensation, post-trial treatment and vulnerable populations.

Also covered are measures related to the drug development phase, including considerations for designing clinical trials, and practical steps to be take during marketing authorisation. Finally, the document provides a summary of regulatory actions.

The deadline for comments is 30 September 2010.

Related news

Show more

Related products

show more

Unlock potential in buffer preparation

Unlock potential in buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 18-Sep-2023 | Infographic

Consider how the right partner can help you scale faster, mitigate risks, and optimize resources.

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 14-Aug-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Automated metadata management in clinical trials

Automated metadata management in clinical trials

Content provided by Formedix | 01-Aug-2023 | White Paper

When it comes to efficient clinical study build, content is king. Most importantly: metadata content. In this blog, we explore the role of metadata in...

Related suppliers

Follow us


View more